Objective To evaluate the safety and efficacy of bevacizumab application as an adjuvant therapy for pterygium excision surgery. Methods In this prospective clinical trial， 95 eyes with unilateral nasal pterygium underwent pterygium excision surgery combined with limbal stem cell autografting， and were assigned into 3 groups at random： group A （32 eyes） did not receive a bevacizumab injection； group B （34 eyes） received a single dose of subconjunctival bevacizumab injection （2.5 mg/0.1 ml） intraoperatively； group C （29 eyes） received subconjunctival bevacizumab injection （2.5 mg/0.1 ml）， one dose intraoperatively and another 2 weeks postoperatively. Patients were followed for 6 months. A one-way analysis of variance， chi-square test， Mann-Whitney and Kruskall-Wallis tests were used for statistical analysis. Results At the end of the study， all stem cell autografts in 3 groups remained alive， with no complications of missing corneal epithelium， erosion or corneal thinning occurring. Pterygium recurrences were only observed in 4 cases in group A， and the occurrence was statistically significant （H=7.50， P<0.05）. No significant difference was found in the clinical efficacy between patients receiving single or double doses of subconjunctival injection. Conclusion Bevacizumab injection combined with limbal stem cell autografting in pterygium excision surgery can effectively inhibit the recurrence of pterygium with no apparent complications. Multiple injections do not yield a better clinical outcome compared to a single dose.
张杨. 贝伐单抗在翼状胬肉手术中的应用[J]. 中华眼视光学与视觉科学杂志, 2014, 16(12): 754-756.
Zhang Yang. The application and effect of Bevacizumab in pterygium surgery. Chinese Journal of Optometry Ophthalmology and Visual science, 2014, 16(12): 754-756. DOI: 10.3760/cma.j.issn.1674-845X.2014.12.012
Coroneo MT， Di Girolamo N， Wakefteld D． The pathogenesis of pterygia[J]． Curt Opin Ophthalmol，1999，10：282-288．
[2]
Gebhardt M， Mentlein R， Schaudig U， et al． Differential expression of vascular endothelial growth factor implies the limbal origin of pterygia[J]． Ophthalmology，2005，112：1023-1030．
[3]
Gueudry J， Richez F， Tougeron-Brousseau B， et al. Subconjunctival bevacizumab for corneal neovascularization[J]. J Fr Ophthalmol，2010，33： 630-636.
[4]
Dastjerdi MH， Al-Arfaj KM， Nallasamy N， et al. Topical bevacizumab in the treatment of corneal neovascularization：results of a prospective， open-label， noncomparative study[J]. Arch Ophthalmol，2009，127：381-389.
[5]
Besharati MR， Manaviat MR， Souzani A. Subconjunctival bevacizumab injection in treatment of pterygium[J]. Acta Med Iran，2011，49：179-183.
[6]
Enkvetchakul O， Thanathanee O， Rangsin R， et al. A randomized controlled trial of intralesional bevacizumab injection on primary pterygium： preliminary results[J]. Cornea，2011，30： 1213-1218.
[7]
Lekhanont K， Patarakittam T， Thongphiew P， et al. Randomized controlled trial of subconjunctival bevacizumab injection in impending recurrent pterygium： a pilot study[J]. Cornea，2012， 2：155-161.
[8]
Shenasi A， Mousavi F， Shoa-Ahari S， et al. Subconjunctival bevacizumab immediately after excision of primary pterygium： the first clinical trial[J]. Cornea，2011，30：1219-1222.
[9]
Prabhasawat P， Barton K， Burkett G， et al. Comparison of conjunctival autografts， amniotic membrane grafts， and primary closure for pterygium excision[J]. Ophthalmology，1997，104：974-985.
[10]
Hosseini H， Nejabat M， Khalili MR. Bevacizumab （Avastin） as a potential novel adjunct in the management of pterygia[J]. Med Hypotheses，2007，69：925-927.
[11]
You IC， Kang IS， Lee SH， et al. Therapeutic effect of subconjunctival injection of bevacizumab in the treatment of corneal neovascularization[J]. Acta Ophthalmol，2009，87：653-658.
[12]
Doctor PP， Bhat PV， Foster CS. Subconjunctival bevacizumab for corneal neovascularization[J]. Cornea，2008，27：992-995.
[13]
Razeghinejad MR， Hosseini H， Ahmadi F，et al. Preliminary results of subconjunctival bevacizumab in primary pterygium excision[J]. Ophthalmic Res，2010，43：134-138.
[14]
Banifatemi M， Razeghinejad MR， Hosseini H， et al. Bevacizumab and ocular wound healing after primary pterygium excision[J]. J Ocul Pharmacol Ther，2011，27：17-21.
[15]
Bhasin P， Gujar P， Bhasin P. A case of recipient bed melt and wound dehiscence after penetrating keratoplasty and subconjunctival injection of bevacizumab[J]. Cornea，2012，31：1342-1343.
[16]
Calcagni M， Althaus MK， Knapik AD， et al. In vivo visualization of the origination of skin graft vasculature in a wild-type/GFP crossover model[J]. Microvasc Res，2011，82：237-245.
[17]
Bahar I， Kaiserman I， McAllum P， et al. Subconjunctival bevacizumab injection for corneal neovascularization in recurrent pterygium[J]. Curr Eye Res，2008，33：23-28.
浙公网安备 33030202001892号